Abstract
A stepwise pharmacological treatment is currently recommended for all asthma patients and is personalized mainly on disease severity, aiming for the lowest disease-controlling step. Nevertheless, asthma comprises several related pathologies with similar clinical manifestations resulting from distinct underlying mechanisms. Therefore novel biomarkers could lead to asthma stratification and thus improve upon the current stepwise approach. The aim of this review is to update the reader with regard to different assays proposed in the recent asthma literature for measuring potential biomarkers for patient stratification and treatment personalization. Promising biomarkers are sputum eosinophils, serum periostin and exhaled nitric oxide. Periostin could differentiate between Th2-high and Th2-low asthma (Th2-high patients are more responsive to glucocorticoids) and the less-defined asthma types which often present a therapeutic challenge. Several other biomarkers, mainly cytokines, leukotrienes and exhaled air components, can be quantified in body fluids and exhaled breath and could also be useful for asthma stratification.
| Original language | English |
|---|---|
| Pages (from-to) | 415-30 |
| Number of pages | 16 |
| Journal | EXPERT REVIEW OF MOLECULAR DIAGNOSTICS |
| Volume | 15 |
| Issue number | 3 |
| Early online date | 5 Dec 2014 |
| DOIs | |
| Publication status | Published - Mar 2015 |
Keywords
- Asthma/diagnosis
- Biomarkers
- Biopsy
- Breath Tests
- Bronchoalveolar Lavage Fluid/cytology
- Cell Adhesion Molecules/metabolism
- Exhalation
- Humans
- Leukocytes
- Nitric Oxide
- Phenotype
- Precision Medicine
- Sputum/cytology
- Th2 Cells/immunology